ArticleFrontiers in cardiovascular medicine2026
The global, regional, and national burden of non-rheumatic degenerative mitral valve disease from 1990 to 2021 and forecast for 2050.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Given the changing epidemiological and burden trends of non-rheumatic degenerative mitral valve disease (DMVD), it is crucial to re-examine geographical differences and trends. Here, we describe the current trends of DMVD epidemiology using data from the Global Burden of Diseases (GBD) study from 1990 to 2021, with forecasts extending to 2050. Methods: Annual case numbers and age-standardized rates (ASR) of incidence, prevalence, deaths, and disability-adjusted life years (DALYs) for DMVD between 1990 and 2021, as well as their estimated annual percentage changes (EAPC), were derived from the 2021 GBD study. Exponential smoothing and autoregressive integrated moving average models are employed for forecasting the future trends of DMVD. Results: Between 1990 and 2021, the number of DMVD incidence cases increased from 566,261 (95% uncertainty interval [UI]: 523,330-609,607) to 1,162,558 (1,084,358-1,244,874), corresponding to a 105.3% (77.9-137.9) rise. Additionally, DMVD-related death cases rose by 53.8% (21.2-97.7), from 23,954 (21,032-26,296) to 36,844 (31,883-41,572). However, there is a decline in ASR of incidence and death. Stratified analysis revealed that the age-standardized incidence rate (ASIR) in males is nearly twice that of females, while the age-standardized death rate (ASDR) is higher in females. These trends are not expected to improve significantly by 2050. Concurrently, the ASIR peaks in individuals aged 65-69 and 70-74. In 2021, higher socio-demographic index (SDI) countries bore a greater DMVD burden, while lower-SDI countries faced greater cross-country inequalities. Conclusions: The number of DMVD epidemiological indicators is rising annually. Higher-SDI countries need to adjust healthcare policies to address aging populations and support lower-SDI countries with medical resources and cardiology expertise. This study suggests that age 65 is a meaningful threshold for screening. Additionally, Our findings advocate for stratified public health interventions: incidence-based screening targeting males and mortality-focused treatment intensification for females.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.